Xcopri - (12.5, 25, 50, 100, 150 and 200 mg ; Tablet)

Generic Name	Cenobamate	Innovator	SK Life
Dosage	12.5, 25, 50, 100, 150 and 200 mg ; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*********	*** \ *********	**** **, ****	*******	****	*** ****** ****, ****
****** ******	*** \ *********	**** **, ****	*******	****	*** ****** ****, ****

Chronology Of Events